Crescent Biopharma, Inc.
Income Statement
| Line Item | FY2013 | FY2012 |
|---|---|---|
| Revenue | $4.0M | $15.3M |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $11.7M | $9.4M |
| SG&A Expense | $2.9M | $2.2M |
| Operating Income | $-10.6M | $3.6M |
| Operating Margin | -265.7% | 23.8% |
| Interest Expense | — | — |
| Pretax Income | — | — |
| Income Tax Expense | — | — |
| Net Income | $-10.6M | $3.7M |
| Net Margin | -265.6% | 24.0% |
| EPS (Basic) | $-0.59 | $0.26 |
| EPS (Diluted) | $-0.59 | $0.02 |
| Shares Outstanding (Basic) | 17.9M | 13.9M |
| Shares Outstanding (Diluted) | 17.9M | 165.2M |
| Dividends Per Share | — | — |